Novo Nordisk and AWS team up to bring agentic AI to drug discovery
Novo Nordisk expands its partnership with AWS, naming it preferred cloud and strategic AI provider while establishing a co-innovation hub in London to accelerate pharmaceutical research.
Stock photo for illustration only, not from the actual event
- AWS becomes Novo Nordisk's preferred cloud and strategic AI partner
- A new co-innovation hub in London brings together pharma scientists and AWS engineers
- Amazon Bio Discovery and AI agents deployed for target identification and therapy design
- Clinical documentation generation time slashed by over 90% using generative AI
Novo Nordisk is scaling up its utilization of Amazon Web Services artificial intelligence tools across the drug discovery pipeline, spanning target identification, therapy design, and research workflows. Under the newly announced agreement, AWS has been appointed as Novo Nordisk's preferred cloud provider and strategic AI partner, alongside the establishment of a co-innovation hub at the pharmaceutical company's facility in London, United Kingdom.
The London-based hub will unite Novo Nordisk R&D staff with AWS engineers, AI specialists, applied scientists, and professional services teams. According to AWS, this arrangement is structured to minimize handoffs between computational analysis and laboratory experimentation as candidate drugs advance through early-stage development phases.
Thilde Hummel Bøgebjerg, executive vice president of Enterprise IT & Quality at Novo Nordisk, stated that the partnership merges advanced artificial intelligence with the company's deep scientific expertise to focus on patient impact. Dan Sheeran, vice president and general manager of Healthcare and Life Sciences at AWS, emphasized that the collaboration centers on applying agentic AI to eliminate persistent bottlenecks across the drug discovery process rather than merely observing them.
Stock photo for illustration only, not from the actual event
The integration of agentic AI systems into pharmaceutical research marks a critical evolution from standard conversational chatbots to autonomous, multi-step workflows. By seamlessly bridging computational biology models with physical laboratory testing and enterprise datasets, these technologies aim to drastically shorten the notoriously lengthy and high-attrition timelines inherent in bringing new medications to clinical trials.
Prior to this broader agreement, Novo Nordisk had already deployed AWS technologies internally. An AWS case study highlights that over 25,000 employees have utilized a generative AI platform built on Amazon Bedrock to power chatbots addressing more than 2,500 use cases. Furthermore, a deployment utilizing Anthropic's Claude 3.5 on Bedrock reduced the time required to generate specific clinical study documentation by over 90%, shrinking a task that previously took 40 to 50 people up to 15 weeks down to just minutes for a team of three, subject to medical professional oversight.
The expanded partnership extends generative AI deeper into actual drug research through tools such as Amazon Bio Discovery, which provides researchers access to over 40 biological AI models orchestrated by AI agents. Additionally, Novo Nordisk plans to leverage Amazon Bedrock AgentCore to execute multi-step workflows across enterprise systems, while maintaining separate collaborations with entities like OpenAI and utilizing Denmark's Gefion supercomputer for intensive data workloads.
Source: AI News
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment